Nordic Fusion Biopsy Market Size & Outlook, 2026-2034
Nordic Fusion Biopsy Market Insights
- As per Reed Intelligence insights, the Nordic Fusion Biopsy Market stood at USD 34.33 Million in 2025 and is anticipated to grow to USD 80.3 Million by 2034.
- The Nordic market is expected to advance at a CAGR of 9.87% from 2026 through 2034.
- In 2025, MRI-Ultrasound Fusion Biopsy accounted for the highest share of the By Type market size.
- During the forecast period, MRI-Ultrasound Fusion Biopsy is set to register the highest growth, making it the most lucrative By Type segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Nordic accounted for 1.89% of the global Fusion Biopsy Market size.
- By 2034, United States is expected to lead the global Fusion Biopsy Market in terms of market size.
- Within Europe, Germany is projected to dominate the regional Fusion Biopsy Market size by 2034.
- Benelux is identified as the fastest-growing market in Europe, anticipated to reach USD 83.84 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2022-2034 |
| Historical Period | 2022-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 34.33 Million |
| Market Size In 2034 | USD 80.3 Million |
| Largest segment | MRI-Ultrasound Fusion Biopsy |
| Units | Revenue in USD Million |
| CAGR | 9.87% (2026-2034) |
| Segmnetation Covered | |
| By Type |
|
| By Application |
|
| By End Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Nordic Fusion Biopsy Market By Type 2026-2034 (USD Million)
| By Type | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRI-Ultrasound Fusion Biopsy | XX.x | XX.x | XX.x | 15.78 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Cognitive Fusion Biopsy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Transperineal Fusion Biopsy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Fusion Biopsy Market By Application 2026-2034 (USD Million)
| By Application | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prostate Cancer Diagnosis | XX.x | XX.x | XX.x | 18.56 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Focal Therapy Planning | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Active Surveillance Monitoring | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Nordic Fusion Biopsy Market By End Use 2026-2034 (USD Million)
| By End Use | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals | XX.x | XX.x | XX.x | 18.4 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Imaging Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ambulatory Surgical Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
